HomeVKTX • NASDAQ
Viking Therapeutics Inc
add
In the news
Financials
Income Statement
Revenue
Net Income
Revenue
Net income
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 46.24M | 57.89% |
Net income | -35.42M | -43.94% |
Net profit margin | — | — |
Earnings per share | -0.32 | -28.00% |
EBITDA | — | — |
Effective tax rate | — | — |
Balance Sheet
Total Assets
Total Liabilities
Total assets
Total liabilities
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 902.61M | 149.29% |
Total assets | 908.32M | 146.50% |
Total liabilities | 28.04M | 39.72% |
Total equity | 880.28M | — |
Shares outstanding | 112.25M | — |
Price to book | 3.75 | — |
Return on assets | -12.52% | — |
Return on capital | -12.89% | — |
Cash Flow
Net Change in Cash
Net change in cash
| (USD) | Dec 2024info | Y/Y change |
|---|---|---|
Net income | -35.42M | -43.94% |
Cash from operations | -31.18M | -76.76% |
Cash from investing | 6.58M | -81.57% |
Cash from financing | 1.00M | 431.91% |
Net change in cash | -23.67M | -229.13% |
Free cash flow | -19.79M | -132.77% |
Previous close
$29.55
Day range
$29.06 - $30.56
Year range
$24.41 - $89.10
Market cap
3.29B USD
Avg Volume
5.20M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
CEO
Founded
2012
Website
Employees
36
